Effectiveness of a multistep *Pseudomonas aeruginosa* eradication treatment protocol in children with cystic fibrosis in Brazil

Barbara Riquena, Luiz Vicente Ribeiro Ferreira da Silva Filho, Cleyde Myriam Aversa Nakaie, Marina Buarque de Almeida, Joaquim Carlos Rodrigues, Fabiola Villac Adde

**ABSTRACT**

**Objective:** Although various strategies have been proposed for eradicating *Pseudomonas aeruginosa* in patients with cystic fibrosis (CF), only a few employ multistep treatment in children colonized by that pathogen for the first time. The aim of this study was to describe the effectiveness of a three-phase eradication protocol, initiated after the first isolation of *P. aeruginosa* in children with CF in Brazil. **Methods:** This was a retrospective real-life study in which we reviewed the medical records of pediatric CF patients in whom the eradication protocol was applied between June of 2004 and December of 2012. The three-phase protocol was guided by positive cultures for *P. aeruginosa* in airway secretions, and the treatment consisted of inhaled colistimethate and oral ciprofloxacin. **Results:** During the study period, 47 episodes of *P. aeruginosa* colonization, in 29 patients, were eligible for eradication. Among the 29 patients, the median age was 2.7 years, 17 (59%) were male, and 19 (65%) had at least one F508del allele. All 29 patients completed the first phase of the protocol, whereas only 12 and 6 completed the second and third phases, respectively. **Conclusions:** In this sample of patients, the multistep eradication protocol was effective and had a high success rate.

**Keywords:** Cystic fibrosis/therapy; Cystic fibrosis/prevention & control; *Pseudomonas aeruginosa*; Treatment outcome.

**INTRODUCTION**

Chronic pulmonary infection with *Pseudomonas aeruginosa* is associated with high morbidity and mortality in patients with cystic fibrosis (CF). *P. aeruginosa* is the most prevalent pathogen causing severe lung disease in patients with CF. *P. aeruginosa* infection can occur very early in life, the risk of death being 2.6 times higher in CF patients infected with *P. aeruginosa* in the first 5 years of life. Once chronic infection is established, *P. aeruginosa* is virtually impossible to eradicate; therefore, early intervention is mandatory.

Several antibiotic strategies for *P. aeruginosa* eradication have been proposed in recent years. Most include inhaled antibiotic therapy in isolation or in combination with systemic antibiotic therapy, and multistep eradication approaches are rarely used. In addition, despite evidence that early eradication of *P. aeruginosa* is beneficial, there are few reports of CF patients receiving eradication treatment upon first isolation of *P. aeruginosa*. Most studies include CF patients with a prior positive airway culture for *P. aeruginosa*. It should be noted that there is currently no standard eradication treatment or evidence that a particular treatment is superior to other treatments.

In 2004, the CF center of the University of São Paulo School of Medicine Hospital das Clínicas Institute for Children, located in the city of São Paulo, Brazil, adopted a multistep *P. aeruginosa* eradication protocol guided by positive cultures for *P. aeruginosa* in airway secretions routinely collected from patients (Figure 1). It is expected that the use of systematic treatment protocols can eradicate initial colonization of the respiratory tract by *P. aeruginosa* in CF patients. A multistep approach is used in order to increase the chance of eradication in cases of new *P. aeruginosa* colonization, through long-term treatment for persistent or early recurrent infection. The objective of the present study was to describe the effectiveness of the multistep eradication protocol used in our institution.

**METHODS**

**Study design**

This was a real-life retrospective cohort study with prospective outcome assessment. Data were collected from the medical records of pediatric patients (under 18 years of age) followed at the CF Outpatient Clinic of the University of São Paulo School of Medicine Hospital das Clínicas, in children with CF in Brazil.
Effectiveness of a multistep *Pseudomonas aeruginosa* eradication treatment protocol in children with cystic fibrosis in Brazil

Clinicas Institute for Children between June of 2004 and December of 2012. The inclusion criteria were as follows: having undergone at least four cultures of airway secretions (oropharyngeal secretions, sputum, or bronchoalveolar lavage fluid) over a 12-month period; having acquired *P. aeruginosa* for the first time; and having undergone our multistep eradication protocol (Figure 2). The study was approved by the Research Ethics Committee of the University of São Paulo School of Medicine Hospital das Clínicas (Ruling no. 1175/24/2014).

**Multistep eradication protocol**

Figure 1 shows a flow chart of our multistep *P. aeruginosa* eradication protocol. Patients with first *P. aeruginosa* isolation were eligible for eradication treatment. Patients were instructed to undergo culture of airway secretions 1-2 weeks after each treatment phase. Patients with a positive culture for *P. aeruginosa* moved on to the second phase of treatment. Those with a positive culture for *P. aeruginosa* after the second phase of treatment moved on to the third. Cases of patients with a negative culture for *P. aeruginosa* after the third phase of treatment were considered to be cases of successful eradication, whereas those of those with a positive culture were considered to be cases of eradication failure.

**Variables and outcomes**

The efficacy of the eradication protocol was evaluated on the basis of culture results after each phase of treatment, a negative culture for *P. aeruginosa* indicating treatment success and a positive culture for *P. aeruginosa* indicating treatment failure.

Clinical and epidemiological data were collected from medical records during routine patient visits. The body mass index was calculated and converted to a z-score by the WHO Anthro Survey Analyser (World Health Organization, Geneva, Switzerland) for children ≤ 5 years of age or by the WHO AnthroPlus software for those > 5 years of age. The Shwachman-Kulczycki score assesses disease severity by scores for physical...
activity, changes in pulmonary propedeutics, nutritional status, and chest X-ray findings, being measured annually in accordance with the institutional protocol.

**Statistical analysis**

Success rates were assessed after each phase, as well as cumulatively, by dividing the number of negative cultures by the number of patients treated in each phase. Descriptive statistics were calculated, including measures of central tendency, measures of dispersion (interquartile range—IQR—and 95% CI), and proportions.

**RESULTS**

Twenty-nine patients were included in the study. Their clinical and epidemiological characteristics are described in Table 1. It is noteworthy that the first colonization by *P. aeruginosa* occurred in preschoolers, most being male.

During the 8.5-year study period, 47 episodes of *P. aeruginosa* colonization, in 29 patients, were eligible for eradication. Of those 47 episodes, 13 (27.7%) were accompanied by pulmonary exacerbations, with hospitalization and intravenous antibiotics being required in only 5.

Of the 47 episodes of *P. aeruginosa* isolation eligible for eradication, 87.2% were episodes of colonization with nonmucoid strains. The mean number of cultures of airway secretions over the course of 12 months was 7 ± 2, and most (75%) of the cultures were cultures of oropharyngeal secretions. The median time elapsed between the end of eradication treatment phase 1 and culture of airway secretions was 16 days (IQR: 6-28 days). The median time elapsed between the end of eradication treatment phase 2 and culture of airway secretions was 35 days (IQR: 14-43 days). The median time elapsed between the end of eradication treatment phase 3 and culture of airway secretions was 43 days (IQR: 31-63 days).

All of the patients included in the present study completed the first phase of the eradication protocol. Eradication was successful in 17, whereas 12 moved on to the second phase of treatment because of a positive culture for *P. aeruginosa* after the first phase. Of those 12 patients, 6 achieved eradication and 6 moved on to the third phase of treatment. Of those 6 patients, 4 achieved eradication and 2 did not (Figure 3). Success rates for eradication in the three treatment phases were 58.6% (95% CI: 40.7-74.5), 50.0% (95% CI: 25.4-74.6), and 66.7% (95% CI: 30.0-90.3), respectively. The cumulative success rate was 93.1% (95% CI: 78.0-98.1).

**DISCUSSION**

To our knowledge, ours is the first study to evaluate a *P. aeruginosa* eradication protocol in pediatric CF patients in Brazil. Our multistep eradication protocol in pediatric CF patients in Brazil. Our multistep eradication protocol was found to be effective in a real-life setting, with a high (93%) success rate. This finding shows that a multistep approach is a therapeutic strategy that can increase the success rate of eradication. However, the success rate after the first phase of treatment was approximately 60%, which is lower than that recently reported in the literature. The reason for this is unknown.

In contrast to most eradication protocols, ours was initiated after the first isolation of *P. aeruginosa*. Other studies have included pediatric CF patients previously infected with *P. aeruginosa* and generally older than those in our sample. A minority received intravenous antibiotic therapy for pulmonary exacerbation at the time of *P. aeruginosa* eradication. We believe that this had no impact on treatment efficacy, given that there is no evidence in the literature that parenteral treatment increases the success of *P. aeruginosa* eradication. The patients included in our study were younger than those in other studies; their median age was 2.7 years, whereas, in other studies, mean ages were 5.5 years and 9 years. This might explain the high success rate in our study, given that structural airway disease is less severe in younger populations. This shows the need for early therapeutic intervention to maximize the chance of success.

Although eradication of *P. aeruginosa* is a well-established treatment, there is insufficient evidence regarding the best approach. There are few studies evaluating the effectiveness of multistep eradication...
Effectiveness of a multistep *Pseudomonas aeruginosa* eradication treatment protocol in children with cystic fibrosis in Brazil

approaches. A CF center in Denmark was the first to publish the results of implementing a multistep protocol for early treatment of *P. aeruginosa* colonization. Patients were treated with nebulized colistimethate and oral ciprofloxacin; drug dose and treatment duration varied across treatment phases, with a maximum duration of 3 months, resulting in a success rate of 78% and improved lung function in the treated patients.\(^{(4)}\) In a study conducted in Italy,\(^{(14)}\) 173 patients received a multistep eradication treatment with nebulized colistimethate and oral ciprofloxacin for 3 weeks in the first phase. In the second phase, patients received double the dose of colistimethate, which was used for 3 months in those who moved on to the third phase of treatment. The success rate was 81%, with a median time of 18 months between eradication and new *P. aeruginosa* acquisition.\(^{(14)}\) In a recently published study conducted at a CF center in

---

**Table 1.** Clinical and laboratory characteristics of patients in each treatment phase.\(^*\)

| Parameter                        | Phase 1 (n = 29) | Phase 2 (n = 12) | Phase 3 (n = 6) |
|----------------------------------|-----------------|-----------------|----------------|
| Female sex                       | 12 (41.4)       | 8 (66.7)        | 4 (66.7)       |
| Age, years                       | 2.7 (0.9-5.3)   | 3.6 (1.9-5.8)   | 3.8 (2.6-4.5)  |
| BMI, z-score                     | −0.4 (−1.0 to −0.7) | −0.4 (−0.8 to −0.9) | −1.2 (−1.6 to −1.1) |
| Genotype, %                      |                 |                 |                |
| Heterozygous *F*508del           | 13 (44.8)       | 4 (33.3)        | 2 (33.3)       |
| Homozygous *F*508del             | 6 (20.7)        | 4 (33.3)        | 1 (16.7)       |
| Other mutations                  | 10 (34.5)       | 4 (33.3)        | 3 (50.0)       |
| Shwachman-Kulczycki score        | 85.0 (85.0-90.0)| 77.5 (72.5-90.0)| 72.5 (60.0-82.5)|
| Pulmonary exacerbation of CF     | 9 (31.0)        | 4 (33.3)        | 1 (16.7)       |
| Coinfection                      |                 |                 |                |
| *Staphylococcus aureus*          | 8 (27.6)        | 5 (41.7)        | 2 (33.3)       |
| MRSA                             | 1 (3.4)         | 1 (8.3)         | 0 (0.0)        |
| *Burkholderia cepacia* complex   | 1 (3.4)         | 2 (16.7)        | 0 (0.0)        |
| Pancreatic status                |                 |                 |                |
| Pancreatic insufficiency          | 26 (86.2)       | 11 (91.7)       | 5 (83.3)       |
| Use of inhaled medications       |                 |                 |                |
| 3% NaCl                           | 1 (3.4)         | 0 (0.0)         | 0 (0.0)        |
| Dornase alfa                     | 3 (10.3)        | 1 (8.3)         | 0 (0.0)        |
| Short-acting β2 agonist          | 4 (13.8)        | 1 (8.3)         | 1 (16.7)       |

BMI: body mass index; CF: cystic fibrosis; and MRSA: methicillin-resistant *Staphylococcus aureus*. \(^*\)Values expressed as n (%) or median (interquartile range).

---

**Figure 3.** Description of the effectiveness of the eradication protocol (cumulative success rate, 93.1%; 95% CI: 78.0-98.1).
In a multicenter study including more than 200 patients, a randomized controlled clinical trial conducted at a CF center in Belgium and including more than 200 patients, eradication therapy with nebulized tobramycin and oral ciprofloxacin for 28 days was not superior to treatment with nebulized tobramycin for 56 days (6-9 months vs. 9-12 months). The authors found that the median time to recurrence of P. aeruginosa was similar between the two groups (6-9 months vs. 9-12 months). The criterion for successful eradication in the present study was a negative culture for P. aeruginosa after the end of each treatment phase. It is known that the primary goal of eradication treatment is to achieve a sustained response (i.e., at least 6 months without P. aeruginosa isolation). However, this was not evaluated in our study, meaning that the eradication success rate might have been overestimated.

In conclusion, our multistep P. aeruginosa eradication protocol appears to be effective in very young CF patients with first P. aeruginosa isolation, with a success rate of 93%. Although many studies have described one-step eradication protocols, the present study demonstrated in a real-life setting that a multistep eradication protocol is effective and sometimes necessary. Larger, long-term multicenter studies with comparator arms evaluating first P. aeruginosa colonization are needed in order to identify the best treatment regimen for P. aeruginosa eradication and the best intervention in cases of failure.

ACKNOWLEDGMENTS

We would like to thank Dr. Claudio Leone for his invaluable aid in evaluating the study results; Dr. Luisa Nunes for providing patient genetic data; and the staff in the Department of Medical Archives of the University of São Paulo School of Medicine Hospital das Clínicas Institute for Children, whose help was essential to complete this study.

REFERENCES

1. Taccetti G, Bianchini E, Cariati L, Buzzetti R, Costantini D, Trevisan F, et al. Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols. Thorax. 2012;67(10):853-859.

2. Taccetti G, Bianchini E, Cariani L, Buzzetti R, Costantini D, Trevisan F, et al. Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols. Thorax. 2012;67(10):853-859.
Effectiveness of a multistep *Pseudomonas aeruginosa* eradication treatment protocol in children with cystic fibrosis in Brazil

859. https://doi.org/10.1136/thoraxjnl-2011-200832

2. Li Z, Kosorok MR, Farrell PM, Laxova A, West SE, Green CG, et al. Longitudinal development of mucoid *Pseudomonas aeruginosa* infection and lung disease progression in children with cystic fibrosis. JAMA. 2005;293(6):581-588. https://doi.org/10.1001/jama.293.5.581

3. Proesmans M, Vermeulen F, Boulanger L, Verhaegen J, De Boeck K. Comparison of two treatment regimens for eradication of *Pseudomonas aeruginosa* infection in children with cystic fibrosis. J Cyst Fibros. 2013;12(1):29-34. https://doi.org/10.1016/j.jcf.2012.06.001

4. Blanchard AC, Horton E, Stanojevic S, Taylor L, Waters V, Ratjen F. Effectiveness of a stepwise *Pseudomonas aeruginosa* eradication protocol in children with cystic fibrosis. J Cyst Fibros. 2017;16(3):396-400. https://doi.org/10.1016/j.jcf.2017.01.007

5. Ratjen F, Munch A, Kho P, Angelos S; ELITE Study Group. Treatment of early *Pseudomonas aeruginosa* infection in patients with cystic fibrosis: the ELITE trial. Thorax. 2010;65(4):286-291. https://doi.org/10.1136/thx.2009.121657

6. Frederiksen B, Koch C, Høiby N. Antibiotic treatment of initial colonization with *Pseudomonas aeruginosa* postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol. 1997;23(5):330-335. https://doi.org/10.1002/(SICI)1099-0496(199705)23:5<330::AID-PPUL4>3.0.CO;2-O

7. Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating *Pseudomonas aeruginosa* in people with cystic fibrosis. Cochrane Database Syst Rev. 2017;4(1):CD004197. https://doi.org/10.1002/14651858.CD004197.pub6

8. Schelstraete P, Haeryck F, Van daele S, Deseyne S, De Baets F. Eradication therapy for *Pseudomonas aeruginosa* colonization episodes in cystic fibrosis patients not chronically colonized by *P. aeruginosa*. J Cyst Fibros. 2013;12(1):1-8. https://doi.org/10.1016/j.jcf.2012.07.008

9. World Health Organization [homepage on the Internet]. Geneva: World Health Organization; [cited 2019 May 6]. WHO Anthro Survey Analyser and other tools [about 2 screens]. Available from: https://www.who.int/childgrowth/software/en/

10. Shvachman H, Kulczycki LL. Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period. AMA J Dis Child. 1958;96(1):8-15. https://doi.org/10.1001/archpedi.1958.02060060000002

11. Triggiani MM, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kulich M, Kronmal R, et al. Comparative efficacy and safety of 4 randomized regimens to treat early *Pseudomonas aeruginosa* infection in children with cystic fibrosis. Arch Pediatr Adolesc Med. 2011;165(8):847-856. https://doi.org/10.1001/archpediatrics.2011.136

12. Mayer-Hamblett N, Kloster M, Rosenfeld M, Gibson RL, Retsch-Bogart GZ, Emerson J, et al. Impact of Sustained Eradication of New *Pseudomonas aeruginosa* Infection on Long-term Outcomes in Cystic Fibrosis. Clin Infect Dis. 2015;61(9):707-715. https://doi.org/10.1093/cid/civ377

13. Littlewood JM, Miller MG, Ghoneim AT, Ramsden CH. Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis. Lancet. 1985;1(8433):865. https://doi.org/10.1016/S0140-6736(85)92222-6

14. Taccetti G, Campana S, Festini F, Mascherini M, Döring G. Early eradication therapy against *Pseudomonas aeruginosa* in cystic fibrosis patients. Eur Respir J. 2005;26(3):458-461. https://doi.org/10.1183/09031936.05.0009605

15. Valerius NH, Koch C, Høiby N. Prevention of chronic *Pseudomonas aeruginosa* colonisation in cystic fibrosis by early treatment. Lancet. 1991;338(8769):725-726. https://doi.org/10.1016/S0140-6736(91)91446-2

16. Athanazio RA, Silva Filho LVRF, Vergara AA, Ribeiro AF, Riedi CA, Prociancy EFA, et al. Brazilian guidelines for the diagnosis and treatment of cystic fibrosis. J Bras Pneumol. 2017;43(3):219-245. https://doi.org/10.1590/s1806-37562017000000065